Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.90M P/E - EPS this Y 81.50% Ern Qtrly Grth -
Income -5.96M Forward P/E -0.74 EPS next Y 32.00% 50D Avg Chg -4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -76.00%
Dividend N/A Price/Book 0.17 EPS next 5Y - 52W High Chg -97.00%
Recommedations 3.00 Quick Ratio 0.51 Shares Outstanding 510.18K 52W Low Chg 12.00%
Insider Own 4.01% ROA -33.58% Shares Float 523.49K Beta -
Inst Own 9.58% ROE -53.11% Shares Shorted/Prior 12.66K/2.20K Price 1.34
Gross Margin - Profit Margin - Avg. Volume 335,922 Target Price 3.00
Oper. Margin - Earnings Date Aug 5 Volume 36,077 Change -4.29%
About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Windtree Therapeutics, Inc. News
05/07/24 Windtree Therapeutics Regains Compliance with Nasdaq
04/18/24 Windtree Therapeutics Announces Reverse Stock Split
04/17/24 Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
04/08/24 Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
02/01/24 Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
01/31/24 Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
01/26/24 Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
01/25/24 Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
01/18/24 Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
01/17/24 Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
01/02/24 Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
09:30 AM Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
12/18/23 Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
11/16/23 Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
11/14/23 Sidoti Events, LLC’s Virtual November Micro-Cap Conference
11/09/23 Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
11/08/23 Windtree to Present at the Sidoti Micro Cap Conference on November 16th
10/12/23 Windtree to Present at the ThinkEquity Conference on October 19th in New York City
10/10/23 Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
10/03/23 Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WINT Chatroom

User Image Austinx Posted - 1 day ago

$WINT Again out of money..they have to do something here soon or the ATM will have to run

User Image Popeye989 Posted - 1 day ago

$WINT $FFIE… we need to do this

User Image JohnDoesit Posted - 2 days ago

$WINT wow dat volume...

User Image Investorrrrr Posted - 2 days ago

$WINT It should have ended at $4.50. At most $4.40 with a sell-off of a few shares.

User Image Austinx Posted - 2 days ago

$WINT 6,249 volume. I guess everyone took today off

User Image almehdawi1976 Posted - 2 days ago

$WINT i think we go up and will see something soon hold ,buy

User Image Investorrrrr Posted - 2 days ago

@Stocktwits @Dollarking @Austinx @harmeyerc I think $WINT will revalue 300% very soon. There is a lot of buying at $4.5 and the company has very valuable assets.

User Image Dollarking Posted - 2 days ago

$WINT Its time for the aquisition now! What has Ladenburg Thalmann come up with so far? What is going on with the inbound business interest that had been created, as it said in PR... What convinced Deerfield to swap in 15 mill debt to 600k shares plus 100 000$ cash

User Image Austinx Posted - 3 days ago

$WINT They better figure something out. No one will buy this if they keep running an ATM

User Image harmeyerc Posted - 3 days ago

$WINT Did We buy Varian out of Palo Alto California? If thats the one, those kids are on a hiring spree?? Look them up on LinkedIn, I just got a notice for regional manager? Not overly invested here so haven't done a deep dive. Austinx is a great resource, so maybe he knows?

User Image Austinx Posted - 3 days ago

$WINT They have diluted since March increased shares to 591,909 from 510,181

User Image Austinx Posted - 3 days ago

$WINT 510,181 shares still and still can’t dilute further until $75M it seems. Out of cash Middle of May 2024. Reduced almost all debt it seems.

User Image DrabooD Posted - 3 days ago

$WINT https://ir.windtreetx.com/node/16746/html 10 q

User Image Austinx Posted - 3 days ago

$WINT They just issued 10-Q. Going to see what share count is and cash position

User Image Austinx Posted - 3 days ago

$WINT Curl up into after hours

User Image Fire_In_My_Eyes Posted - 3 days ago

$WINT I need just under $9 to break even from pre-split average. Anything above that is profits.

User Image jgoose93 Posted - 3 days ago

$WINT don’t tease what you can’t please!! 😣

User Image Investorrrrr Posted - 3 days ago

$WINT I expect $20 soon

User Image Fire_In_My_Eyes Posted - 3 days ago

$WINT Should I get excited?? Or is this another tease??

User Image marvelousTrades Posted - 3 days ago

It is really very strange to see $MI and $WINT not getting any love despite their nano floats. We need whales here..anyone 🐋

User Image TonytheeInvestor Posted - 3 days ago

$WINT setting up nicely …there are a few trendlines of resistance but I think we break them on the way up with good volume and it is possible with major news this can rip 20-30x because of float and shares outstanding …posters saying 20 target are wrong and shortsighted …this has good potential for mid 50s minimum in my opinion 50 low end 100 high end 💎 good luck

User Image almehdawi1976 Posted - 3 days ago

$WINT 100$ why not???

User Image rp6577 Posted - 3 days ago

$WINT a bit of news and this will rip hard 🔥 $XBI

User Image ButterCapital Posted - 3 days ago

$WINT nibbling

User Image Dollarking Posted - 3 days ago

$WINT Give us 30$ for a starter Craig

User Image Dollarking Posted - 3 days ago

$WINT Something seems to be happening

User Image Austinx Posted - 3 days ago

$WINT Locked my shares at $40 for now

User Image rp6577 Posted - 4 days ago

$AMC $GME $WINT okay this might be happening……could go absolutely bananas! 🔥🚀🚀

User Image rp6577 Posted - 4 days ago

$AMC $GME $WINT it would go absolutely parabolic!

User Image Investorrrrr Posted - 4 days ago

@Stocktwits I prefer $WINT Minimum 52 week, high/low $35.0997/$3.721. All this downside to get to a ridiculous $2 million capitalization and shit like Jaguar Health is still worth $74 million being a worse company. It could be worth $100 but the market is irrational, I expect at least a 300% rise soon.

Analyst Ratings
HC Wainwright & Co. Neutral Jan 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fraser Craig President and CEO President and CEO Sep 27 Buy 1.0199 2,500 2,550 57,877 09/28/23
Fraser Craig President and CEO President and CEO Sep 26 Buy 0.90 2,500 2,250 55,377 09/27/23
Fraser Craig President and CEO President and CEO Apr 26 Buy 1.77 1,497 2,650 7,010 04/27/23
Fraser Craig President and CEO President and CEO Apr 25 Buy 1.89 1,315 2,485 5,513 04/26/23
Hamill John P. SVP & CFO SVP & CFO Jul 26 Buy 0.3666 3,000 1,100 72,800 07/26/22
Fraser Craig President and CEO President and CEO Jul 26 Buy 0.374 2,500 935 224,058 07/26/22
Fraser Craig President and CEO President and CEO Jun 29 Buy 0.4154 7,000 2,908 217,058 06/30/22
Fraser Craig President and CEO President and CEO Mar 16 Buy 0.9799 2,000 1,960 210,058 03/17/22
Simonson Steven SVP, Chief Medical O.. SVP, Chief Medical Officer Mar 15 Buy 0.9998 5,000 4,999 83,602 03/15/22
Fraser Craig President and CEO President and CEO Mar 15 Buy 0.9801 3,000 2,940 208,058 03/15/22
Center Laboratories, Inc. 10% Owner 10% Owner May 20 Buy 4.43 1,294,260 5,733,572 1,239,088 01/10/22
Bioengine Capital Inc. 10% Owner 10% Owner May 20 Buy 7.25 55,172 399,997 1,239,088 01/10/22
Bioengine Capital Inc. 10% Owner 10% Owner May 20 Sell 1.6 1,239,088 1,982,541 01/10/22